LLY Stock Price Today (September 2026) — Eli Lilly and Company Analysis & Key Metrics 2026-09-04
Eli Lilly and Company (LLY) is trading at $1149.36, down 0.88% today (as of September 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $1315.04 (14.4% upside).
- Volatility remains elevated (28.10% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (47.70% YoY) alongside significant competitive pressures.
LLY Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Eli Lilly and Company - Historical Price & Volume
Market Cap
Enterprise Value: $1.08T
P/E Ratio
Forward P/E: 24.49
Revenue Growth
Year over Year
Analyst Target
+14.4% upside potential
Key Investor Questions About LLY
What investors need to know before buying
Based on current market data, LLY presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 37.04)
- Fundamentals say: Caution warranted (high leverage concerns)
LLY's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for LLY investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $54.91B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, LLY stock traded between $712.05 and $1292.65—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 28.10% annualized volatility and β=0.58, the stock exhibits low sensitivity to market moves—making LLY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Eli Lilly’s $100B incretin opportunity: Is more upside coming?
Investing.com -- Eli Lilly & Co is positioned for further growth in the booming obesity-drug market, with its Zepbound and Mounjaro treatments and a pipeline of next-generation therapies offering multiple avenues for upside, J.P. Morgan said in a research note.
Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock
Is this big pharma stock still a buy for investors who aren't billionaires?
Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years
Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does.
Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
MarketBeat Week in Review – 08/31 - 09/04
Stocks pulled back after a strong jobs report stoked rate-hike concerns. MarketBeat writers recap earnings-season themes, covering AI, cybersecurity, retail, energy, and dividend stocks.
Lilly Launches Foundayo in the UK as NICE Review Continues
Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Its launch […]
Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared Elecsys pTau217, which is a blood test that helps identify whether […]
Jim Cramer flagged one stock quietly concentrating portfolios
The portfolio looks diversified. Cramer says look again
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.
Explore More Analysis for LLY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Eli Lilly and Company
Eli Lilly and Company (LLY) is currently trading at $1149.36. The RSI (14-day) is at 37.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $1315.04 implies 14.4% upside from current levels. Volatility is moderate at 28.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Eli Lilly and Company (LLY): The trailing P/E ratio is 39.12, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 24.49, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.48, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 30.24. Price-to-Sales is 12.87. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering LLY, the consensus price target is $1315.04. This represents a 14.4% upside from the current price of $1149.36. The range spans from a low target of $850.00 to a high target of $1600.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Eli Lilly and Company (LLY) pays a dividend with a current yield of approximately 60.00%. The annualized dividend rate is $6.46 per share. The payout ratio is 21.7%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-08-14T00:00:00.000Z.
Key risks for Eli Lilly and Company (LLY) investors include: 1. Moderate volatility (28.1% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 162.07) which could pressure margins in a rising rate environment. 3. Elevated short interest (74.0% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Eli Lilly and Company's (LLY) current debt and financial health profile: Total debt stands at $54.91B. The debt-to-equity ratio is 162.07, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.35, indicating adequate short-term liquidity. The quick ratio is 0.68. The company holds $8.95B in cash and equivalents. Free cash flow is positive at $11.07B, providing a cushion for debt servicing and shareholder returns.